| WB | 1/200-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | MIG9 |
| WB Predicted band size | 10 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human S100P |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于S100P抗体的代表性文献摘要(基于公开研究整理，非真实引用)：
---
1. **文献名称**: *S100P antibody as a potential diagnostic marker for pancreatic cancer*
**作者**: Smith A, et al.
**摘要**: 研究报道S100P蛋白在胰腺癌组织中高表达，使用特异性S100P抗体进行免疫组化分析，发现其敏感性和特异性优于传统标志物CA19-9.提示其作为新型诊断工具的潜力。
---
2. **文献名称**: *S100P promotes breast cancer metastasis via RAGE signaling: Evidence from antibody-blocking experiments*
**作者**: Chen L, et al.
**摘要**: 通过S100P抗体阻断实验，证实S100P通过结合RAGE受体激活MAPK通路，促进乳腺癌细胞迁移和侵袭，为靶向S100P-RAGE轴的治疗策略提供依据。
---
3. **文献名称**: *Development of a novel monoclonal S100P antibody for colorectal cancer prognosis*
**作者**: Wang Y, et al.
**摘要**: 开发了一种高亲和力单克隆S100P抗体，应用于结直肠癌患者组织样本检测，发现S100P高表达与患者总生存期缩短显著相关，可作为独立预后标志物。
---
**备注**：以上内容为示例性概括，实际文献需通过PubMed等数据库检索关键词“S100P antibody”获取具体信息。
The S100P antibody targets the S100 calcium-binding protein P (S100P), a member of the S100 protein family characterized by EF-hand calcium-binding domains. S100P is implicated in cellular processes such as proliferation, differentiation, and apoptosis, often dysregulated in cancer. Initially identified in placental tissue, S100P is overexpressed in various malignancies, including pancreatic, gastric, colorectal, and breast cancers, where it correlates with tumor progression, metastasis, and poor prognosis. Its interaction with the receptor for advanced glycation end products (RAGE) activates pro-survival signaling pathways like NF-κB and MAPK, promoting tumor cell survival and invasion.
S100P antibodies are widely used in research and diagnostics to detect S100P expression via techniques like immunohistochemistry (IHC), Western blotting, and immunofluorescence. These tools help elucidate S100P's role in tumor microenvironments, stromal interactions, and therapeutic resistance. Studies also explore its potential as a biomarker for early cancer detection or monitoring treatment response. Beyond oncology, S100P is studied in inflammatory and developmental contexts due to its regulatory functions in embryogenesis and tissue repair. Recent interest focuses on blocking S100P-RAGE signaling as a therapeutic strategy, with antibodies aiding in target validation and drug development. Despite progress, challenges remain in understanding tissue-specific regulation and clinical translation of S100P-targeted approaches.
×
